Oncodesign maintains its revenue and operating income at €38 million in 2020…

Oncodesign maintains its revenue and operating income at €38 million in 2020 and is anticipating an operating profit for the 2nd straight year, within the context of the global public health crisis [EN]

Oncodesign maintains its revenue and operating income at €38 million in 2020 and is anticipating an operating profit for the 2nd straight year, within the context of the global public health crisis

  • Revenue and operating income maintained at €38.3 million (-3%)
  • 2020 Group revenue of €25.5 million, down slightly (- 5%) after the exceptional growth of 34% recorded in 2019
  • The Service BU’s contribution to Group revenue remained stable at €21.1 million, offering good prospects for 2021 with a sharp increase in the order book (+36%)
  • Biotech BU recurring revenue of €3.4 million, up 20%; over €1 million in milestone payments in 2020
  • Solid cash position of €28.8m, including €15.9m in State-Guaranteed Loan financing
  • Finalization of the structuring of the Group into three Business Units

Paris and Dijon (France), June 14, 2021 at 06:00pm CEST– Servier and Oncodesign (ALONC – FR0011766229) today announced the selection of a preclinical candidate resulting from their strategic collaboration to find new treatments for Parkinson’s disease.

Read the pdf

Share: